- Home
- KZIA vs COEP Comparison
KZIA vs COEP Comparison
Compare KZIA & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | COEP |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | Australia | United States |
| Employees | N/A | 6 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 91.2M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | KZIA | COEP |
|---|---|---|
| Price | $12.95 | $16.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 229.2K | 81.9K |
| Earning Date | 06-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $6.80 |
| 52 Week High | $17.40 | $21.41 |
Technical Indicators
Market Signals| Indicator | KZIA | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 72.18 |
| Support Level | $5.71 | $13.77 |
| Resistance Level | $14.82 | $19.19 |
| Average True Range (ATR) | 1.03 | 1.15 |
| MACD | -0.30 | 0.47 |
| Stochastic Oscillator | 35.24 | 87.62 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.